Shun Lu

机构：Ningbo University, Guangzhou University of Chinese Medicine, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai Cancer Institute, ZheJiang Academy of Agricultural Sciences, Ningbo University Affiliated Hospital, Hôpital de la Timone, Ningbo First Hospital, Weifang University · ORCID：0000-0003-3887-4320

发表论文 102 篇 · 总被引 2337 次 · h-index 27

代表论文

• Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC (2024 · New England Journal of Medicine · 被引 424)
• Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial (2024 · European Journal of Cancer · 被引 83)
• Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions (2025 · Nature Reviews Clinical Oncology · 被引 51)
• LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12 (2024 · Annals of Oncology · 被引 10)
• A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). (2025 · Journal of Clinical Oncology · 被引 6)
• Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 (2025 · Journal of Clinical Oncology · 被引 5)